Aplastic Anemia: Understanding Your Disease and Treatment Options
|
|
- Bertram Tate
- 6 years ago
- Views:
Transcription
1 APPROXIMATE BLOOD CELL REQUIREMENTS Aplastic Anemia: Understanding Your Disease and Treatment Options Danielle Townsley, MD, MSc Associate Director, Oncology AztraZeneca Medimmune cell type total number life span daily production (days) neutrophils 2 x 2 x platelets x x erythrocytes 3 x x AN HEMATOPOIETIC STEM CELL NEUTROPHIL DIFFERENTIATION Myeloblast Promyelocyte Myelocyte Metamyelocyte Band Segmented neutrophil Pathophysiology of Aplastic Anemia Immune attack (T lymphocytes) Hematopoietic Stem Cells Hematopoietic Progenitors Circulating blood cells
2 % Surviving Cause of Aplastic Anemia/Immune attack on stem cells BONE MARROW FAILURE SYNDROMES AA/PNH PNH LGL Most of the cases of Aplastic Anemia have no identifiable cause SDS Pregnancy, eosinophilic fasciitis, and seronegative hepatitis are associated with AA AA Drugs and chemicals have been reported (Benzene, Chloramphenicol) DKC AML All identifiable triggers explain very few cases of AA AID: MS, IBD, uveitis, DM type, etc. hypocellular MDS MDS MAJOR PROSPECTIVE EPIDEMIOLOGIC STUDIES Europe/Israel (IAAAS): 2/million (Kaufman DW et al: The Drug Etiology of Agranulocytosis and Aplastic Anemia; 99, Oxford) Thailand (NHLBI): 4.4/million (Issarigrisil S et al: Am J Hematol 999; 6:64; Blood 26 7:299) China: 7.4/million (C Yang, X Zhang: Chin Med Sci J 99; 6:23) BLEEDING MANIFESTATIONS OF THROMBOCYTOPENIA AGE AT DIAGNOSIS Aplastic Anemia Admissions to NIH Clinical Center NATURAL HISTORY OF APLASTIC ANEMIA Utah, total (n = 99) Severity Criteria (two of three): platelets <2K/uL reticulocytes <% (6K/uL) ANC <5/uL Super-severe: ANC <2/uL AA 2 Study Utah, extrapolated severe Group, non-transplanted (n = 63) Years Camitta et al, Blood 53:54, 979 Williams et al, Sem Hematol :95, 973 2
3 96 s % survival in year Immunosuppressive therapy Bone marrow transplantation 2 9% survival in year Supportive care Iron Chelation Blood Banking Antifungals Immunosuppressive therapy Therapy terminology Treatment Naïve Anti-thymocyte globulin (ATG) Horse Rabbit Cyclosporine (CsA) Refractory Salvage Therapy Relapsed Term remission not used Anti-thymocyte Globulin (ATG) Production Immunization with human thymocytes Xenogeneic polyclonal antibodies RESPONSE OF SEVERE APLASTIC ANEMIA TO INTENSIVE IMMUNOSUPPRESSION 7, 6, 5, 4, 3, CSA ATG ANC 2,, 24-Sep 4-Oct 4-Oct 24-Oct 3-Nov 3-Nov 23-Nov 3-Dec 3-Dec 23-Dec 2-Jan 2-Jan 22-Jan Thymus T Tx Tx Hct 55, 5, 45, 4, 35, 3, 25, Retic 2, 26 5, Sep 4-Oct 3-Nov 23-Nov 3-Dec 2-Jan, 22-Jan 3 ATG IgG Cytotoxicity assay Purification of sera Tx Tx Tx Tx Platelets 24-Sep 4-Oct 4-Oct 24-Oct 3-Nov 3-Nov 23-Nov 3-Dec 3-Dec 23-Dec 2-Jan 2-Jan 22-Jan 3
4 patients plateletsl x /ml Survival PROGRESS IN IMMUNOSUPPRESSIVE THERAPIES FOR SEVERE APLASTIC ANEMIA Era Drug Response 96s corticosteroids ~% (occasional) 97s ATGs 4-5% 98s ATG plus CSA 6-7% Study Years N Median Age (years) Response Relaps e Clonal Evolution Survival German % 9% 8% 58% at yrs NIH % 35% % 55% at 7 yrs EGMBT % 2% % 87% at 5 yrs Japan % 22% 6% 88% at 3 yrs German/A ustrian INTENSIVE IMMUNOSUPPRESSION FOR SAA COMPARISON OF RESULTS % 2% 6% 87% at 4yrs Japan % 42% 8% 88% at 4 yrs NIH % 37% 9% 8% at 4 yrs EGBMT % 33% 4% 76% at 6 yrs NIH % 26% % 93% at 3yrs NIH % 28% 2% 96% at 3 yrs Young NS, Calado RT, Scheinberg P. Blood 26 ATG AND CSA FOR SEVERE APLASTIC ANEMIA OVERALL SURVIVAL Cytogenetics % response rate Days 4 47, 45, 46, XY, XY+8-7 [] ATG Evolution ATG 6 Evolution ATG CsA CsA TRISOMY CsA response no response 35 3 Evolution Years After Diagnosis 5 5 normal trisomy 8 5q- monosomy 7 Probability Probability of response of response according to age according to age Scheinberg P et al. J Pediatrics 28. 4
5 Survival probability Survival probability Survival probability Survival Survival Probability in Children Survival in refractory SAA 99s. Overall Responders to IST no response Log rank P< Days 4 Improved Survival Over Time Improved Survival Over Time yr survival = 8% yr survival = 74% yr survival = 94% yr survival = 92% yr survival = 9% All patients N = 42 p<. Time (years) yr survival = 64% Responders to IST N = 246 p= Time (years) Improved Survival Over Time ATTEMPTS TO IMPROVE OUTCOMES OF IST FOR SAA yr survival = 66% Add to or replace ATG with megadose corticosteroids No increase in response; high toxicity (Marmontl, Prog Clin Biol Res 984) Replace ATG with high dose cyclophosphamide Toxicity (Tisdale, Lancet 2; Blood 22) Replace ATG with moderate dose cyclophosphamide Excessive toxicity secondary to neutropenia (Scheinberg, Blood 24) yr survival = 37% Add mycophenolate mofetil to ATG/CsA No improvement in response/survival (Scheinberg, Br J Haematol 26) Add sirolimus to ATG/CsA No improvement in response/survival (Scheinberg, Haematologica 29).2 Non-responders to IST N = 74 p<. Time (years) yr survival = 23% Add G-CSF to ATG/CsA No improvement in response/survival (Locasciulli, Haematologica 24) Prolonged CsA (2 years) to prevent relapse Delayed but ultimately equivalent rate (Scheinberg, Am J Hematol 24) Replace horse with rabbit ATG, or alemtuzumab, frontline No improvement in response/survival (Scheinberg, NEJM 22) Clin Infect Dis 5: 726, 2 5
6 Proportion evolving ELTROMBOPAG (EPAG) A NON-PEPTIDE TPO RECEPTOR AGONIST ELTROMBOPAG AND APLASTIC ANEMIA CLINICAL APPLICATIONS Orally administered, t /2 3 hrs. FDA accelerated approval for chronic ITP (28). 4% (7/43) hematologic response rate Durable tri- and bilineage responses Transfusion independence Well-tolerated ELTROMBOPAG FOR REFRACTORY SAA Lineage characteristics of responses Initial Trial-EPAG for Refractory Severe Aplastic Anemia 6 Weeks-Primary Endpoint Best Response at Follow-up P H P H 43 patients refractory to immunosuppressive therapy (median 2.5 cycles) mg daily Dose escalation every 2 weeks to 5 mg daily Primary endpoint Hematologic response 2-6 weeks Responders continue EPAG until robust response or plateau 4 N Platelets Neutrophils Hemoglobin 4 N Subset of non-responders had improvement in counts at 3 months and/or continued improvement in counts and decreased transfusion frequency after EPAG stopped Would extended treatment with EPAG improve response rate in refractory SAA? Olnes et al. NEJM 22 Desmond et al. Blood, 24 Extended Dosing with EPAG for Refractory SAA CLONAL CYTOGENETIC EVOLUTION HISTORIC COHORT 5 mg daily No dose escalation 4 patients refractory to IST (median.5 cycles) Platelet count 3,/µL, ANC <5/µL, Hb<9. g/dl 3 month evaluation Hematologic response 6 month evaluation Primary Endpoint Hematologic response Responders continue EPAG until robust response or plateau All evolution Evolution to monosomy 7 2 responders at 6 months (5%) 3 multi-lineage 5/2 responders were non-responders at 3 months N at risk all evolution mono Days Thomas Winkler, ASH 27 clinicaltrials.gov NCT89994 Scheinberg & Young. Blood 22 6
7 CYTOGENETIC EVOLUTION REFRACTORY SAA ELTROMBOPAG FOR REFRACTORY SAA Can EPAG be discontinued? Pooled analysis of all 83 patients enrolled in both EPAG studies for rsaa 6 patients (8%) had clonal evolution Detected early (3 mo), rarely with dysplasia 6 patients-loss of chromosome 7 or 7q (5 nonresponders) 9 patients-other cytogenetic abnormalities (normalized in 5) patient with AML (no metaphase growth at baseline) Stopping criteria: Robust response: Platelets >5,/ul Hb > g/dl Neutrophils >,/ul or stable counts x 6m 5 robust responders had EPAG stopped - 3 relapses, responded to EPAG - 2 (8%) with durable response, median f/u 3 years Thomas Winkler, ASH 27 clinicaltrials.gov NCT89994 Desmond R et al. Blood 22;23:2 Thomas Winkler, ASH 27 TPO AND HEMATOPOIETIC STEM CELLS ELTROMBOPAG FOR TREATMENT NAÏVE SAA TPO receptor (c-mpl) expressed on HSCs and early progenitor cells TPO expands HSCs in vitro stimulation to expand HSC pool: increase response rate? accelerate count recovery? prevent HSC depletion? avoid clonal progression? Immune attack IST (-) HSC growth factors (+) C-Mpl and Tpo knockout mice have reduced HSCs probability of failure probability of recovery Multi-lineage marrow failure occurs in some congenital amegakaryocytic thrombocytopenia Stem cell number Yoshihara Cell Stem Cell 27; Alexander Blood 996; Qian Cell Stem Cell 27; Ballmaier Ann N Y Acad Sci 23 ELTROMBOPAG ADDED TO STANDARD IST Treatment Naïve SAA HEMATOLOGIC RESPONSE RATES 92 patients 3 months Cohort N=3 Cohort 2 N=3 Cohort 3 N=3 All Cohorts N=92 N (%) N (%) N (%) N (%) Historic rates N=388* OR 23 (77) 24 (77) 27 (87) 74 (8) 6% 5 year follow-up CR 5 (7) 8 (26) 5 (48) 28 (3) 6 months 8% OR 24 (8) 27 (87) 29 (94) 8 (87) 63% CR (33) 8 (26) 8 (58) 36 (39) 2% Townsley DM, et al. NEJM 27; 376:54-5. Townsley DM, et al. NEJM 27; 376:
8 ROBUST COUNT RECOVERY IN RESPONDERS EPAG V. HISTORIC MEDIAN TIME TO BLOOD COUNT RECOVERY 2 Platelets Neutrophils Neutrophils in very SAA ANC>5/uL: 48 days 5 per μl 5 ** per μl 3 2 ** Red cells Transfusion independence: 39 days Baseline IST + EPAG Historic IST 3 months 6 months Baseline 3 months 6 months Platelets Transfusion independence: 32 days Townsley DM, et al. NEJM 27; 376:54-5. Townsley DM, et al. NEJM 27; 376:54-5. BONE MARROW ANALYSIS ADVERSE EVENTS Townsley DM, et al. NEJM 27; 376:54-5. Townsley DM, et al. NEJM 27; 376:54-5. OVERALL SURVIVAL MEDIAN FOLLOW-UP 23 MONTHS RELAPSE MEDIAN FOLLOW-UP X MONTHS 97% at 2 years (95% CI, 94-%) Townsley DM, et al. NEJM 27; 376 One () death on study: Thymoma with paraneoplastic encephalopathy Two (2) deaths after HSCT MDS/AML: HSCT relapsed AML Relapsed aplastic anemia: HSCT GVHD Townsley DM, et al. NEJM 27; 376:54-5. Townsley DM, et al. 57 th ASH 25 Townsley DM, et al. manuscript under review 8
9 2.% % of Patients with Gene Type 8.% 4.%.% A SUBSET OF MUTATIONS CORRELATE WITH SURVIVAL - FREE FROM CLONAL EVOLUTION PIGA DNMT3A Splicing JAKs TP53 Mutation Status in AA (n=256) 23% 5% 7% negative mutation 2 mutations 3 mutations PIGA BCOR/BCORL DNMT3A ASXL SETBP PRC2 LAMB4 TERF/TERT PHF6 RIT 65% IDH2 RBBP4 PRPF8 One-third with at least mutation Yoshizato T et al. N Engl J Med 25;373:35-47 multiple missense nonsense frameshift splicing MPL POT STAT3 DIS3 Yoshizato T et al. N Engl J Med 25;373:35-47 SIMILAR PROPORTION OF PATIENTS WITH MUTATIONS AFTER IST+ELTROMBOPAG IST + EPAG 3 (3%) (%) 6 (8%) 7 (78%) Yoshizato, et al. NEJM 25 5% 7% negative mutation 2 mutations 3 mutations 23% 65% 35% with mutations Townsley DM, ASH 26 Yoshizato T et al. N Engl J Med 25;373: /9 (22%) patients 6 with one gene mutation Chromosome Instability CONSEQUENCES OF TELOMERE EROSION TELOMERES AND CLONAL EVOLUTION EVOLUTION RATE aneuploidy p53 Senescence/ Apoptosis (Hayflick phenomenon)) Telomere length of leucocytes at diagnosis of SAA predicts clonal evolution end-to-end fusion non-reciprocal translocation Scheinberg P et al, J Am Med Assoc 2; 34:358 9
10 TPO level (pg/ml) TPO level (pg/ml) Normalized telomere length TELOMERES AND CLONAL EVOLUTION TELOMERES AND A SEX HORMONE EPAG Stable SAA controls Clonal evolution Months since SAA treatment Predictors for response to EPAG + IST Longer Telomeres (> th percentile) Younger Age Accelerated telomere loss precedes clonal evolution to 7-27 patients with telomere diseases, short telomeres ± mutations were enrolled, study closed early for efficacy (telomere elongation) Dumitriu B, et al. Blood 25; 25:76 Townsley DM, Dumitriu B, et al. N Engl J Med 26;374: THE HIGH TPO PARADOX HOW DOES EPAG IMPROVE HEMATOPOIESIS DESPITE HIGH TPO LEVELS? Endogenous TPO levels are already markedly elevated in patients with severe aplastic anemia (AA) Severe AA ITP Emmons R et al., Blood 87:468 (996) Severe AA Healthy controls Feng X et al., Haematologica 96:62 (2) Dr. Andre Larochelle Heterodimerization of TPO and IFNγ Impairs Human Hematopoietic Stem/Progenitor Cell Signaling and Survival in Chronic Inflammation TPO AND EPAG BIND TO c-mpl AT DISTINCT SITES Thrombopoietin Cytokine Small molecule 59 th ASH Annual Meeting, Plenary Session Luigi J. Alvarado, Hai Cheng, Heather D. Huntsman, Alessio Andreoni, Danielle Townsley, Thomas Winkler, Xingmin Feng, Jay R. Knutson, Cynthia E. Dunbar, Neal S. Young, Andre Larochelle National Heart, Lung, and Blood Institute (NHLBI) National Institutes of Health (NIH) December th, 27 Thrombopoietin (TPO) Signaling pathways c-mpl extracellular domain Hematopoietic stem/progenitor cell (HSPC) Survival Proliferation c-mpl transmembrane domain Signaling pathways Hematopoietic stem/progenitor cell (HSPC)
11 Number of CFC per 3 cells % human CD45+ cells SSC-A % CD34+ cells in BM CD34+ cell count INFLAMMATORY CYTOKINES ARE ELEVATED IN APLASTIC ANEMIA EPAG MAINTAINS MORE CD34+ HSPCs THAN TPO IN THE PRESENCE OF IFNɣ IN VITRO TCR Ag IFNɣ promoter APC T cell IFNɣ SAP Fyn SLAM SLAM.. Ap la s tic p a tie n ts N o r m a l in d iv id u a ls Normal HSPC (CD34+) Alvarado LJ, ASH 27 TPO day ex vivo culture +/- Interferon-γ TPO or eltrombopag Maintenance of CD34+ HSPCs Without IFNɣ With IFNɣ CD34+ cell count HSPC survival and function Without W o u t IFNγ N With IFNγ N Adapted from Young NS et al, Blood 8 (8): 259 (26) CD34 n=26 TPOP O E m b o p a g EPAG MAINTAINS STEM AND PROGENITOR CELLS IN THE PRESENCE OF IFNɣ IN VITRO Model of IFNγ-Mediated Bone Marrow Failure Signaling Inhibition by TPO:IFNγ Heteromers in Human HSPCs Colony forming cell (CFC) assay Transplantation into NSG mice TPO Thrombopoietin (TPO) c-mpl IFNγ occludes TPO:c-MPL low-affinity site C F U s p e r 3 c e lls Without W o u t IF NIFNγ With IFIFNγ N n.s. % h u m a C D c e lls Without IFNγ With IFNγ n.s. Heteromers Signaling + Signaling IFNɣ HSPC survival/proliferation c-mpl n=3 T P O TPO E p a g TPO E E + I T T+ I Signaling + IFNɣ Signaling TPO c-mpl IFNγ CD45+ = human cell engraftment (HSCs) HSPC survival/proliferation Alvarado LJ, ASH 27 SUMMARY EPAG is an effective single agent for refractory severe AA, and in combination with IST associates with markedly higher response rates European (RACE) Trial ongoing ages 5 Global (SOAR) Trial CSA/EPAG for severe AA NIH Extension Trial - ongoing In tx naive SAA, clonal evolution rates similar to IST without EPAG, but longer follow up required to establish late events Somatic myeloid cancer mutations are common in adults with AA, but unclear clinical utility beyond standard cytogenetics Insights into mechanism suggest EPAG may ameliorate cytopenias in other inflammatory states (GVHD, chronic infections) National Institutes of Health Neal S. Young Cynthia E. Dunbar Phillip Scheinberg Thomas Winkler Rodrigo Calado Ronan Desmond Bogdan Dumitriu Katherine Calvo Fernanda Rodrigues Janet Valdez Feng Xingmin Andre Larochelle Keyvan Keyvanfar Stephanie Sellers Sachiko Kajigaya Marie Desierto Harshraj Leuva Charles Bolan Olga Rios Barbara Weinstein Margaret Bevans ACKNOWLEDGEMENTS GSK, Novartis Connie Erickson-Miller Nicole Stone Krista McKerracher Brian Elliott JoAnn Horowitz Socorro Portella Katie McNamara Kelly Haines Neogenomics Maher Albitar Wanlong Ma Univ of Chicago Soma Das Zejuan Li
Aplastic Anemia: Current Thinking on Disease, Diagnosis and Non- Transplant Treatment
4/18/212 Aplastic Anemia: Current Thinking on Disease, Diagnosis and Non- Transplant Treatment Bogdan Dumitriu, MD Hematology Branch National, Heart, Lung and Blood Institute National Institutes of Health
More informationAplastic Anemia: Current Thinking on Disease, Diagnosis and Non- Transplant Treatment
7/23/212 Aplastic Anemia: Current Thinking on Disease, Diagnosis and Non- Transplant Treatment Danielle Townsley, MD, MSc Hematology Branch National, Heart, Lung and Blood Institute National Institutes
More informationAplastic Anemia: Understanding your Disease and Treatment Options
Aplastic Anemia: Understanding your Disease and Treatment Options No financial relationships or commercial interest related to the content of this presentation Josh Sasine, MD, PhD Hematopoietic Cell Transplant
More informationThe function of the bone marrow. Living with Aplastic Anemia. A Case Study - I. Hypocellular bone marrow failure 5/14/2018
The function of the bone marrow Larry D. Cripe, MD Indiana University Simon Cancer Center Bone Marrow Stem Cells Mature into Blood Cells Mature Blood Cells and Health Type Function Term Red Cells Carry
More informationAAMDSIF. Aplastic Anemia Research Summary from the DIAGNOSIS RTEL1 Mutations and Bone Marrow Failure
AAMDSIF Aplastic Anemia Research Summary from the 2016 AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING A Summary of Selected Scientific Abstracts for Patients with Aplastic Anemia and Their Caregivers DIAGNOSIS
More informationShall young patients with severe aplastic anemia without donors receive BMT from alternative source of HCT? Elias Hallack Atta, MD, PhD
Shall young patients with severe aplastic anemia without donors receive BMT from alternative source of HCT? Elias Hallack Atta, MD, PhD Declaração de Conflito de Interesse Declaro que possuo conflito de
More informationOverview of Aplastic Anemia. Overview of Aplastic Anemia. Epidemiology of aplastic anemia. Normal hematopoiesis 10/6/2017
Overview of Aplastic Anemia Overview of Aplastic Anemia Peter Westervelt, MD, PhD Professor of Medicine Chief, BMT/Leukemia Section Washington University School of Medicine Epidemiology Normal hematopoiesis
More informationOutline. What is aplastic anemia? 9/19/2012. Aplastic Anemia Current Thinking on the Disease, Diagnosis, and Non-Transplant Treatment Options
Aplastic Anemia Current Thinking on the Disease, Diagnosis, and Non-Transplant Treatment Options Carlos M. de Castro, MD Duke University Medical Center Outline What is Aplastic Anemia? What other diseases
More information3/31/2014. New Directions in Aplastic Anemia Treatment: What s on the Horizon? Objectives
New Directions in Aplastic Anemia Treatment: What s on the Horizon? AA & MDS International Foundation Living with, MDS, or PNH Patient and Family Conferences in 2014 April 5, 2014 Objectives To provide
More informationCynthia Fata, MD, MSPH 6/23/15
Cynthia Fata, MD, MSPH 6/23/15 Clinical case presentation Introduction to thrombopoietin Development of thrombopoietic agents Clinical Indications Eltrombopag use in aplastic anemia Future uses 33 yo F
More informationImmunosuppressive treatment in acquired aplastic anemia. André Tichelli Hematology, University Hospital Basel
Immunosuppressive treatment in acquired aplastic anemia André Tichelli Hematology, University Hospital Basel Why is immunosuppressive treatment a choice for acquired aplastic anemia? Hematopoietic stem
More informationPacientes jovens sem doador com anemia aplástica grave devem receber TMO de fonte alternativa de CTH NO!
Pacientes jovens sem doador com anemia aplástica grave devem receber TMO de fonte alternativa de CTH NO! Phillip Scheinberg, MD Head, Clinical Hematology Hospital A Beneficência Portuguesa de Sao Paulo
More informationHow I treat acquired aplastic anemia
How I treat acquired aplastic anemia Phillip Scheinberg and Neal S. Young Blood Volume 120(6):1185-1196 August 9, 2012 2012 by American Society of Hematology Symptoms, Signs, and Lab Findings Bruising,
More informationImmunotherapies for aplastic anemia
Workshop on Hematology and Bone Marrow Transplant May 11 12, 2018, São Paulo Immunotherapies for aplastic anemia Diego Villa Clé, MD, PhD Attending Physician Hospital das Clínicas Faculdade de Medicina
More information9/9/2015 HISTORY & EPIDEMIOLOGY. Objectives. Textbook Definition of Aplastic anemia (AA) Epidemiology. History
Objectives Aplastic Anemia: Current Thinking on the Disease, Diagnosis, and Non-Transplant Treatment Amy E. DeZern, MD, MHS Assistant Professor of Oncology and Medicine The Johns Hopkins University School
More informationAplastic Anaemia Genomics: Current data and interpretation
An Academic Health Sciences Centre at the heart of a world city... Aplastic Anaemia Genomics: Current data and interpretation Austin G Kulasekararaj Consultant Haematologist King s College Hospital, London
More informationNot So Benign Hematology. Robert A. Brodsky, MD Johns Hopkins Family Professor of Medicine and Oncology Division Chief Hematology
Not So Benign Hematology Robert A. Brodsky, MD Johns Hopkins Family Professor of Medicine and Oncology Division Chief Hematology Disclosures Dr. Brodsky serves as a Scientific Advisory Board member to:
More informationEltrombopag Added to Standard Immunosuppression for Aplastic Anemia
The new england journal of medicine Original Article Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia Danielle M. Townsley, M.D., Phillip Scheinberg, M.D., Thomas Winkler, M.D., Ronan
More informationYes Antonio M. Risitano, M.D., Ph.D. Head of Bone Marrow Transplantation Unit Federico II University of Naples
4ème Journée Nationale Maladies Rares Immuno-Hématologiques Paris, June 7th 2018 Matched unrelated upfront transplantation in idiopathic aplastic anemia? Yes Antonio M. Risitano, M.D., Ph.D. Head of Bone
More informationAplastic Anemia. is a bone marrow failure disease 9/19/2017. What you need to know about. The 4 major components of blood
What you need to know about Aplastic Anemia Stuart Goldberg MD Aplastic Anemia is a bone marrow failure disease The bone marrow is the factory that makes blood The 4 major components of blood Red Blood
More informationUse of TPO mimetics for Indications Other Than ITP
Use of TPO mimetics for Indications Other Than ITP Mazyar Shadman, MD, MPH Discussant: Siobán Keel, MD Hematology Fellows Conference June 28, 2013 Thrombopoietin (TPO) and other c mpl ligands TPO mimetics
More informationNot So Benign Hematology Aplastic anemia, Paroxysmal Nocturnal Hemoglobinuria, atypical Hemolytic Uremic Syndrome, Thrombotic Thrombocytopenic Purpura
Not So Benign Hematology Aplastic anemia, Paroxysmal Nocturnal Hemoglobinuria, atypical Hemolytic Uremic Syndrome, Thrombotic Thrombocytopenic Purpura Robert A. Brodsky, MD Johns Hopkins Family Professor
More informationMUD HSCT as first line Treatment in Idiopathic SAA. Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK
MUD HSCT as first line Treatment in Idiopathic SAA Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK No Financial Disclosures Guidelines for management of aplastic anaemia British
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the author to give readers additional information about his work. Supplement to: Olnes MJ, Scheinberg P, Calvo KR, et al. Eltrombopag and improved
More informationPromacta (eltrombopag)
Promacta (eltrombopag) Policy Number: 5.01.542 Last Review: 5/2018 Origination: 6/2013 Next Review: 5/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Promacta
More informationAplastic Anemia: Fill Er Up! But With What? Speaker s Disclosure Statement. Objectives. Aplastic Anemia: Fill Er Up? But With What?
Fill Er Up! But With What? Karyn Brundige, MSN, CPNP Dana-Farber/Boston Children s Cancer and Blood Disorders Center karyn.brundige@childrens.harvard.edu Speaker s Disclosure Statement I have no industry
More information7/12/2016 TESTING. Objectives. New Directions in Aplastic Anemia: What's on the Horizon? Better way to evaluate clonal evolution?
New Directions in Aplastic Anemia: What's on the Horizon? Amy E. DeZern, MD; MHS Assistant Professor Hematologic Malignancies Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, MD Objectives
More information3/31/2014. Aplastic Anemia: Current Thinking on the Disease, Diagnosis, and Non-Transplant Treatment. Objectives
Aplastic Anemia: Current Thinking on the Disease, Diagnosis, and Non-Transplant AA & MDS International Foundation 2014 Living with Aplastic Anemia, MDS, or PNH Patient and Family Conferences (Los Angeles
More informationClinical significance of acquired somatic mutations in aplastic anaemia
Int J Hematol (2016) 104:159 167 DOI 10.1007/s12185-016-1972-8 PROGRESS IN HEMATOLOGY Recent advance in the diagnosis and treatment of bone marrow failure syndromes Clinical significance of acquired somatic
More informationTherapeutic Advances in Treatment of Aplastic Anemia. Seiji Kojima MD. PhD.
Therapeutic Advances in Treatment of Aplastic Anemia Seiji Kojima MD. PhD. Department of Pediatrics Nagoya University Graduate School of Medicine Chairman of the Severe Aplastic Anemia Working Party Asia-Pacific
More informationNontransplant therapy for bone marrow failure
Nontransplant therapy for bone marrow failure Danielle M. Townsley and Thomas Winkler BONE MARROW FAILURES Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD Nontransplant therapeutic
More informationOUTCOME AFTER IMMUNOSUPPRESSION
OUTCOME AFTER IMMUNOSUPPRESSION EBMT Aplastic Anemia Educational Meeting Budapest November 1 st 2012 Antonio M. Risitano, M.D., Ph.D. Head of Bone Marrow Transplant Unit Hematology, DBBM Federico II University
More informationSESSION 1 Reactive cytopenia and dysplasia
SESSION 1 Reactive cytopenia and dysplasia Falko Fend, Tübingen & Alexandar Tzankov, Basel 1 Disclosure of speaker s interests (Potential) conflict of interest none Potentially relevant company relationships
More informationeltrombopag (Promacta )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationSevere Aplastic Anemia in Children and Adolescents. Brigitte Strahm 21. April 2018
Severe Aplastic Anemia in Children and Adolescents Brigitte Strahm 21. April 2018 Acquired Aplastic Anemia in children What is aquired aplastic anemia? Camitta, Blood 1976 How A.L.G. acts is unknown, but
More informationClonality & Aplastic anemia / PNH
Clonality & Aplastic anemia / PNH What is in a word W Shakespear : Hamlet Prof G SOCIE, MD, PhD Head Division of Hematology / Immunology / Oncology French reference Center Aplastic Anemia & PNH Hospital
More informationObjectives. What is Aplastic Anemia. SAA 101: An Introductory Course to Severe Aplastic Anemia
SAA 101: An Introductory Course to Severe Aplastic Anemia David A. Margolis, MD Professor of Pediatrics/Medical College of Wisconsin Program Director/ Children s Hospital of Wisconsin BMT Program Objectives
More informationMDS 101. What is bone marrow? Myelodysplastic Syndrome: Let s build a definition. Dysplastic? Syndrome? 5/22/2014. What does bone marrow do?
101 May 17, 2014 Myelodysplastic Syndrome: Let s build a definition Myelo bone marrow Gail J. Roboz, M.D. Director, Leukemia Program Associate Professor of Medicine What is bone marrow? What does bone
More informationShould we still use Camitta s criteria for severe aplastic anemia?
VOLUME 47 ㆍ NUMBER 2 ㆍ June 2012 THE KOREAN JOURNAL OF HEMATOLOGY ORIGINAL ARTICLE Should we still use Camitta s criteria for severe aplastic anemia? Hyun Hwa Yoon, Seok Jae Huh, Ji Hyun Lee, Suee Lee,
More informationLate Complications Following Treatment for Severe Aplastic Anemia (SAA) with High-Dose Cyclophosphamide (Cy): Follow up of a Randomized Trial
Blood First Edition Paper, prepublished online June 28, 2002; DOI 10.1182/blood-2002-02-0494 Late Complications Following Treatment for Severe Aplastic Anemia (SAA) with High-Dose Cyclophosphamide (Cy):
More informationThrombopoietin Receptor Agonists Prior Authorization with Quantity Limit Program Summary
Thrombopoietin Receptor Agonists Prior Authorization with Quantity Limit Program Summary Thrombopoietin Receptor Agonists Prior Authorization with Quantity Limit OBJECTIVE The intent of the prior authorization
More informationDisclosers Updates: Management of Aplastic Anemia and Congenital Marrow Failure 5/9/2017
2017 Updates: Management of Aplastic Anemia and Congenital Marrow Failure Sachit Patel, MD Department of Pediatrics Division of Hematology-Oncology Blood and Marrow Transplantation Disclosers None 1 Objectives:
More informationParoxysmal nocturnal hemoglobinuria clones in severe aplastic anemia patients treated with horse anti-thymocyte globulin plus cyclosporine
Paroxysmal nocturnal hemoglobinuria clones in severe aplastic anemia patients treated with horse anti-thymocyte globulin plus cyclosporine Phillip Scheinberg, Michael Marte, Olga Nunez, and Neal S. Young
More informationthrombopoietin receptor agonists and University of Washington January 13, 2012
Tickle me eltrombopag: thrombopoietin receptor agonists and the regulation of platelet production Manoj Menon University of Washington January 13, 2012 Outline Clinical case Pathophysiology of ITP Therapeutic
More informationDiagnosis and Management of Immune Thrombocytopenias. Thomas L. Ortel, M.D., Ph.D. Duke University Medical Center 2 November 2016
Diagnosis and Management of Immune Thrombocytopenias Thomas L. Ortel, M.D., Ph.D. Duke University Medical Center 2 November 2016 Disclosures Research support: NIH, CDC, Eisai, Pfizer, Daiichi Sankyo, GlaxoSmithKline,
More informationPROMACTA (eltrombopag olamine) oral tablet and oral suspension
PROMACTA (eltrombopag olamine) oral tablet and oral suspension Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit
More informationIdelalisib treatment is associated with improved cytopenias in patients with relapsed/refractory inhl and CLL
Idelalisib treatment is associated with improved cytopenias in patients with relapsed/refractory inhl and CLL Susan M O Brien, Andrew J Davies, Ian W Flinn, Ajay K Gopal, Thomas J Kipps, Gilles A Salles,
More informationLet s Look at Our Blood
Let s Look at Our Blood Casey O Connell, MD Associate Professor of Clinical Medicine Jane Anne Nohl Division of Hematology Keck School of Medicine of USC 10,000,000,000 WBCs/day Bone Marrow: The Blood
More informationBor-Sheng Ko. Hematology Division, Department of Internal Medicine, National Taiwan University Hospital
Bor-Sheng Ko Hematology Division, Department of Internal Medicine, National Taiwan University Hospital On behalf of Members of Aplastic Anemia Consensus Meeting Diagnosis and classification: Treatment
More informationNot So Benign Hematology. Robert A. Brodsky, MD Johns Hopkins Family Professor Director of Adult Hematology
Not So Benign Hematology Robert A. Brodsky, MD Johns Hopkins Family Professor Director of Adult Hematology Disclosures Dr. Brodsky serves as a Scientific Advisory Board member to: Alexion Pharmaceuticals
More informationPharmacy Prior Authorization
Pharmacy Prior Authorization AETA BETTER HEALTH PESLVAIA & AETA BETTER HEALTH KIDS Promacta (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review
More informationJAK2 Inhibitors for Myeloproliferative Diseases
JAK2 Inhibitors for Myeloproliferative Diseases Srdan (Serge) Verstovsek M.D., Ph.D. Associate Professor Department of Leukemia University of Texas MD Anderson Cancer Center Houston, Texas, USA Myeloproliferative
More informationYear 2002 Paper two: Questions supplied by Jo 1
Year 2002 Paper two: Questions supplied by Jo 1 Question 70 A 25 year old previously well male student presents with recent exertional dyspnoea, epistaxis and bruising. There is no history of medication,
More informationAplastic Anemia and related bone marrow failures. Ryotaro Nakamura, MD Department of Hematology/HCT City of Hope National Medical Center Duarte, CA
Aplastic Anemia and related bone marrow failures Ryotaro Nakamura, MD Department of Hematology/HCT City of Hope National Medical Center Duarte, CA CONFLICTS OF INTEREST Advisory Board meetings: Merck,
More informationCurrent guidelines for management of INT- 2/high risk MDS
ELASTIC Current guidelines for management of INT- 2/high risk MDS If fit (i.e. HCT-CI and performance status< 3), consider for early allo BMT with/without prior AML induction therapy If unfit consider
More informationBorder between aplastic anemia and myelodysplastic syndrome
Int J Hematol (2013) 97:558 563 DOI 10.1007/s12185-013-1324-x PROGRESS IN HEMATOLOGY Advances in the management of acquired aplastic anemia (AA) Border between aplastic anemia and myelodysplastic syndrome
More informationNovità nelle MDS. Matteo G Della Porta. Cancer Center IRCCS Humanitas Research Hospital & Humanitas University Rozzano Milano, Italy
Novità nelle MDS Matteo G Della Porta Cancer Center IRCCS Humanitas Research Hospital & Humanitas University Rozzano Milano, Italy matteo.della_porta@hunimed.eu Outline ARCH Predictive value of somatic
More informationAplastic Anemia: Current Thinking
Aplastic Anemia: Current Thinking ANDREW C. DIETZ, MD, MSCR PEDIATRIC BLOOD AND MARROW TRANSPLANTATION CHILDREN S HOSPITAL LOS ANGELES, UNIVERSITY OF SOUTHERN CALIFORNIA Outline Ø What is Aplastic Anemia?
More informationMyelodysplastic Syndrome: Let s build a definition
1 MDS: Diagnosis and Treatment Update Gail J. Roboz, M.D. Director, Leukemia Program Associate Professor of Medicine Weill Medical College of Cornell University The New York Presbyterian Hospital Myelodysplastic
More informationAplastic Anemia and related bone marrow failures. Ryotaro Nakamura, MD Department of Hematology/HCT City of Hope National Medical Center Duarte, CA
Aplastic Anemia and related bone marrow failures Ryotaro Nakamura, MD Department of Hematology/HCT City of Hope National Medical Center Duarte, CA CONFLICTS OF INTEREST Advisory Board meetings: Merck,
More informationAplastic Anemia Pathophysiology and Approach to Therapy
Aplastic Anemia Pathophysiology and Approach to Therapy BSMCON 2018 Dr. Syed Ghulam Mogni Mowla MBBS, FCPS, FACP Introduction Aplastic anaemia (AA) is the paradigm of the human bone marrow failure syndromes
More informationAndrew Schorr: Dr. Young, for patients receiving initial treatment could you discuss the findings comparing horse ATG and rabbit ATG?
What s New in Aplastic Anemia Treatment American Society of Hematology Meeting December 2011 Dr. Neal S. Young Please remember the opinions expressed on Patient Power are not necessarily the views of our
More informationOutline. Case Study 5/17/2010. Treating Lower-Risk Myelodysplastic Syndrome (MDS) Tapan M. Kadia, MD Department of Leukemia MD Anderson Cancer Center
Treating Lower-Risk Myelodysplastic Syndrome (MDS) Tapan M. Kadia, MD Department of Leukemia MD Anderson Cancer Center Outline Case Study What is lower-risk MDS? Classification systems Prognosis Treatment
More information2. Does the patient have a diagnosis of chronic idiopathic thrombocytopenic purpura (ITP)?
Pharmacy Prior Authorization MERC CARE (MEDICAID) Promacta (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax
More informationPharmacy Prior Authorization
Pharmacy Prior Authorization MERC CARE (MEDICAID) Promacta (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax
More informationMyelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data
Instructions for Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data (Form 2114) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the Myelodysplasia/Myeloproliferative
More informationMDS: Who gets it and how is it diagnosed?
MDS: Who gets it and how is it diagnosed? October 16, 2010 Gail J. Roboz, M.D. Director, Leukemia Program Associate Professor of Medicine Weill Medical College of Cornell University The New York Presbyterian
More informationASH 2011 aktualijos: MSC TPŠL gydyme. Mindaugas Stoškus VULSK HOTC MRMS
ASH 2011 aktualijos: MSC TPŠL gydyme Mindaugas Stoškus VULSK HOTC MRMS #3042. Yukiyasu Ozawa et al. Mesenchymal Stem Cells As a Treatment for Steroid-Resistant Acute Graft Versus Host Disease (agvhd);
More informationPathophysiology 7/18/2012 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
PAROXYSMAL NOCTURNAL HEMOGLOBINURIA OUTLINE OF DISCUSSION WHAT IS IT WHO GETS IT NATURAL HISTORY TYPES RISKS COURSE TREATMENTS SYMPTOMS PREGNANCY Pathophysiology Acquired hematopoietic stem cell disorder
More informationPeking University People's Hospital, Peking University Institute of Hematology
Qian Jiang, M.D. Peking University People's Hospital, Peking University Institute of Hematology No. 11 Xizhimen South Street, Beijing, 100044, China. Phone number: 86-10-66583802 Mobile: 86-13611115100
More informationThe Immune System. A macrophage. ! Functions of the Immune System. ! Types of Immune Responses. ! Organization of the Immune System
The Immune System! Functions of the Immune System! Types of Immune Responses! Organization of the Immune System! Innate Defense Mechanisms! Acquired Defense Mechanisms! Applied Immunology A macrophage
More informationMyelodysplastic Syndrome Case 158
Myelodysplastic Syndrome Case 158 Dong Chen MD PhD Division of Hematopathology Mayo Clinic Clinical History 86 year old man Persistent borderline anemia and thrombocytopenia. His past medical history was
More informationINHERITED PANCYTOPENIA SYNDROMES Fanconi anemia Shwachman-Diamond syndrome Dyskeratosis congenita Congenital amegakaryocytic thrombocytopenia
The Pancytopenias The Inherited Pancytopenias Pancytopenia refers to a reduction below normal values of all 3 peripheral blood component: leukocytes, platelets, and erythrocytes. Pancytopenia requires
More informationMyelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management
Received: 2 October 2017 Accepted: 2 October 2017 DOI: 10.1002/ajh.24930 ANNUAL CLINICAL UPDATES IN HEMATOLOGICAL MALIGNANCIES Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and
More informationStem Cell Transplantation for Severe Aplastic Anemia
Number of Transplants 10/24/2011 Stem Cell Transplantation for Severe Aplastic Anemia Claudio Anasetti, MD Professor of Oncology and Medicine Chair, Blood and Marrow Transplant Dpt Moffitt Cancer Center
More informationAplastic Anemia Research Summary from the 2017 AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING A
AAMDSIF Aplastic Anemia Research Summary from the 2017 AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING A Summary of Selected Scientific Abstracts for Patients with Aplastic Anemia and Their Caregivers DIAGNOSIS
More informationSummary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain
Summary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain EHA 2017 ANNUAL MEETING: ABSTRACT SEARCH PAGE: https://learningcenter.ehaweb.org/eha/#!*listing=3*browseby=2*sortby=1*media=3*ce_id=1181*label=15531
More informationBiTE in ALL and AML. Ibrahim Aldoss, MD Assistant Professor, City of Hope Hematology and Hematopoietic Cell Transplantation
BiTE in ALL and AML Ibrahim Aldoss, MD Assistant Professor, City of Hope Hematology and Hematopoietic Cell Transplantation Disclosure I am consultant for Helocyte and Speaker Bureau for JAZZ Immune system
More informationConcomitant WT1 mutations predicted poor prognosis in CEBPA double-mutated acute myeloid leukemia
Concomitant WT1 mutations predicted poor prognosis in CEBPA double-mutated acute myeloid leukemia Feng-Ming Tien, Hsin-An Hou, Jih-Luh Tang, Yuan-Yeh Kuo, Chien-Yuan Chen, Cheng-Hong Tsai, Ming Yao, Chi-Cheng
More informationEmerging Treatment Options for Myelodysplastic Syndromes
Emerging Treatment Options for Myelodysplastic Syndromes James K. Mangan, MD, PhD Assistant Professor of Clinical Medicine Abramson Cancer Center, University of Pennsylvania Please note that some of the
More informationChronic Myelomonocytic Leukemia with molecular abnormalities SH
Chronic Myelomonocytic Leukemia with molecular abnormalities SH2017-0351 Madhu P. Menon MD,PhD, Juan Gomez MD, Kedar V. Inamdar MD,PhD and Kristin Karner MD Madhu P Menon, MD, PhD Henry Ford Hospital Patient
More informationTreatment of low risk MDS
Treatment of low risk MDS Matteo G Della Porta Cancer Center IRCCS Humanitas Research Hospital & Humanitas University Rozzano Milano, Italy matteo.della_porta@hunimed.eu International Prognostic Scoring
More informationAcute Myeloid Leukemia with RUNX1 and Several Co-mutations
Case SH2017-0281 Acute Myeloid Leukemia with RUNX1 and Several Co-mutations James Bauer, MD, PhD David Yang, MD Erik Ranheim, MD, PhD Catherine Leith, MB, Bchir Clinical History Chief Complaint: 72 year
More informationDISCLOSURE Luca Malcovati, MD. No financial relationships to disclose
ICUS, CCUS and CHIP Luca Malcovati, MD Department of Molecular Medicine, University of Pavia Medical School, & Department of Hematology Oncology, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy DISCLOSURE
More informationAnemia (3).ms Hemolytic Anemia. Abdallah Abbadi Feras Fararjeh
Anemia (3).ms4.26.2.18 Hemolytic Anemia Abdallah Abbadi Feras Fararjeh Case 3 24 yr old female presented with anemia syndrome and jaundice. She was found to have splenomegaly. Hb 8, wbc 12k, Plt 212k,
More informationOne Day BMT Course by Thai Society of Hematology. Management of Graft Failure and Relapsed Diseases
One Day BMT Course by Thai Society of Hematology Management of Graft Failure and Relapsed Diseases Piya Rujkijyanont, MD Division of Hematology-Oncology Department of Pediatrics Phramongkutklao Hospital
More informationTable 1: biological tests in SMD
Table 1: biological tests in SMD Tests Mandatory Recommended Under validation Morphology Marrow aspirate Marrow biopsy 1 Iron staining Quantification of dysplasia WHO 2008 Classification Cytogenetics Conventional
More informationMyeloproliferative Disorders - D Savage - 9 Jan 2002
Disease Usual phenotype acute leukemia precursor chronic leukemia low grade lymphoma myeloma differentiated Total WBC > 60 leukemoid reaction acute leukemia Blast Pro Myel Meta Band Seg Lymph 0 0 0 2
More informationHorse versus Rabbit Antithymocyte Globulin in Acquired Aplastic Anemia
The new england journal of medicine original article Horse versus Rabbit Antithymocyte Globulin in Acquired Aplastic Anemia Phillip Scheinberg, M.D., Olga Nunez, R.N., B.S.N., Barbara Weinstein, R.N.,
More information5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow
5/9/2018 or Stem Cell Harvest Where we are now, and What s Coming AA MDS International Foundation Indianapolis IN Luke Akard MD May 19, 2018 Infusion Transplant Conditioning Treatment 2-7 days STEM CELL
More informationDepartment of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 2 Sunesis Pharmaceuticals, Inc, South San Francisco
Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) Naval Daver 1, Hagop Kantarjian 1, Guillermo
More informationCHALLENGING CASES PRESENTATION
CHALLENGING CASES PRESENTATION Michael C. Wiemann, MD, FACP Program Co-Chair and Vice President Indy Hematology Education President, Clinical St. John Providence Physician Network Detroit, Michigan 36
More informationMYELODYSPLASTIC SYNDROMES: A diagnosis often missed
MYELODYSPLASTIC SYNDROMES: A diagnosis often missed D R. EMMA W YPKEMA C O N S U LTA N T H A E M AT O L O G I S T L A N C E T L A B O R AT O R I E S THE MYELODYSPLASTIC SYNDROMES DEFINITION The Myelodysplastic
More informationLay Summaries ASH 2017
Lay Summaries ASH 2017 Purpose of Document: This document contains a collection of lay summaries of accepted ASH 2017 abstracts from the following investigators: MDS CRC Members/Affiliates, Fellows (past
More informationHaploidentical Transplantation today: and the alternatives
Haploidentical Transplantation today: and the alternatives Daniel Weisdorf MD University of Minnesota February, 2013 No matched sib: where to look? URD donor requires close HLA matching and 3-12 weeks
More informationUnderstanding & Treating Myelodysplastic Syndrome (MDS)
Understanding & Treating Myelodysplastic Syndrome (MDS) Casey O Connell, MD Associate Professor of Clinical Medicine Jane Anne Nohl Division of Hematology Keck School of Medicine of USC Let s Look at Our
More informationMDS-004 Study: REVLIMID (lenalidomide) versus Placebo in Myelodysplastic Syndromes with Deletion (5q) Abnormality
MDS-4 Study: REVLIMID (lenalidomide) versus Placebo in Myelodysplastic Syndromes with Deletion (5q) Abnormality TABLE OF CONTENTS Section 1. Executive Summary Section 2. Background Section
More informationACCME/Disclosures. History. Hematopathology Specialty Conference Case #4 4/13/2016
Hematopathology Specialty Conference Case #4 Sherrie L. Perkins MD, PhD University of Utah ACCME/Disclosures The USCAP requires that anyone in a position to influence or control the content of CME disclose
More informationReview of Aplastic Anemia Guidelines. Seiji Kojima MD. PhD.
Review of Aplastic Anemia Guidelines Seiji Kojima MD. PhD. Department of Pediatrics Nagoya University Graduate School of Medicine Chairman of the Severe Aplastic Anemia Working Party Asia-Pacific Blood
More information7/13/2017. PreventionGenetics. How are genes associated with bone marrow failure?
Personalized Medicine: tic Testing and the Implications for Future Therapies Preventiontics Michael Chicka, PhD, Molecular ticist, Preventiontics Founded in 2004 in Marshfield Wisconsin by Dr. Jim Weber
More information